<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Bioinvent International Ab — News on 6ix</title>
<link>https://6ix.com/company/bioinvent-international-ab</link>
<description>Latest news and press releases for Bioinvent International Ab on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 23 Feb 2026 09:15:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/bioinvent-international-ab" rel="self" type="application/rss+xml" />
<item>
<title>BioInvent Announces Nomination of Two New Board Members Ahead of 2026 Annual General Meeting</title>
<link>https://6ix.com/company/bioinvent-international-ab/news/bioinvent-announces-nomination-of-two-new-board-members-ahead-of-2026-annual-general-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/bioinvent-international-ab/news/bioinvent-announces-nomination-of-two-new-board-members-ahead-of-2026-annual-general-meeting</guid>
<pubDate>Mon, 23 Feb 2026 09:15:00 GMT</pubDate>
<description>Kate Hermans: Global life sciences executive with 25+ years of leadership across biopharma, commercial strategy, global operations, and value-creation transformations in both public and venture-backed companies Scott Zinober: Senior investment professional ...</description>
</item>
<item>
<title>BioInvent Reports Promising Data from Ongoing Phase 2a study for BI-1808 with KEYTRUDA(R) (pembrolizumab) in Recurrent Ovarian Cancer</title>
<link>https://6ix.com/company/bioinvent-international-ab/news/bioinvent-reports-promising-data-from-ongoing-phase-2a-study-for-bi-1808-with-keytrudar-pembrolizumab-in-recurrent-ovarian-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/bioinvent-international-ab/news/bioinvent-reports-promising-data-from-ongoing-phase-2a-study-for-bi-1808-with-keytrudar-pembrolizumab-in-recurrent-ovarian-cancer</guid>
<pubDate>Mon, 05 Jan 2026 06:45:00 GMT</pubDate>
<description>24% ORR for BI-1808 combined with pembrolizumab represents a meaningful improvement over pembrolizumab monotherapy in recurrent ovarian cancer (8% ORR in KEYNOTE-100) The combination demonstrated a favorable safety and tolerability profile Results ...</description>
</item>
<item>
<title>BioInvent to Participate in Upcoming Investor Conference</title>
<link>https://6ix.com/company/bioinvent-international-ab/news/bioinvent-to-participate-in-upcoming-investor-conference</link>
<guid isPermaLink="true">https://6ix.com/company/bioinvent-international-ab/news/bioinvent-to-participate-in-upcoming-investor-conference</guid>
<pubDate>Thu, 18 Dec 2025 13:10:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / December 18, 2025 /BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, ...</description>
</item>
<item>
<title>BioInvent Presents Impressive Response Data from Ongoing Phase 2a Trial of Triple Combination BI-1206, Rituximab, and Calquence in r/r NHL at ASH 2025</title>
<link>https://6ix.com/company/bioinvent-international-ab/news/bioinvent-presents-impressive-response-data-from-ongoing-phase-2a-trial-of-triple-combination-bi-1206-rituximab-and-calquence-in-rr-nhl-at-ash-2025</link>
<guid isPermaLink="true">https://6ix.com/company/bioinvent-international-ab/news/bioinvent-presents-impressive-response-data-from-ongoing-phase-2a-trial-of-triple-combination-bi-1206-rituximab-and-calquence-in-rr-nhl-at-ash-2025</guid>
<pubDate>Mon, 08 Dec 2025 13:10:00 GMT</pubDate>
<description>Early data indicate that BI-1206 has the potential to reset one of the main resistance mechanisms to rituximab 47% of patients exhibited complete responses (CR), with an overall response rate of 80% Favorable safety profile with most (87%) adverse ...</description>
</item>
<item>
<title>BioInvent Presents Promising Early Phase 2a BI-1808 Monotherapy Data in CTCL at ASH 2025</title>
<link>https://6ix.com/company/bioinvent-international-ab/news/bioinvent-presents-promising-early-phase-2a-bi-1808-monotherapy-data-in-ctcl-at-ash-2025</link>
<guid isPermaLink="true">https://6ix.com/company/bioinvent-international-ab/news/bioinvent-presents-promising-early-phase-2a-bi-1808-monotherapy-data-in-ctcl-at-ash-2025</guid>
<pubDate>Sun, 07 Dec 2025 13:15:00 GMT</pubDate>
<description>BioInvent International (STO:BINV) 46% objective response rate (6 of 13 evaluable patients) and a 92% disease control rate (12 of 13) in relapsed/refractory CTCL Immune activation confirmed by CD8+ T cell infiltration and granzyme B elevation in skin ...</description>
</item>
<item>
<title>BioInvent Announces Publication of Preclinical and Early Phase 1 Data for BI-1607 in HER2-Positive Advanced Solid Tumors</title>
<link>https://6ix.com/company/bioinvent-international-ab/news/bioinvent-announces-publication-of-preclinical-and-early-phase-1-data-for-bi-1607-in-her2-positive-advanced-solid-tumors</link>
<guid isPermaLink="true">https://6ix.com/company/bioinvent-international-ab/news/bioinvent-announces-publication-of-preclinical-and-early-phase-1-data-for-bi-1607-in-her2-positive-advanced-solid-tumors</guid>
<pubDate>Tue, 18 Nov 2025 13:15:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / November 18, 2025 / BioInvent International (STO:BINV): Most (78%) patients experienced disease control (stable disease), including heavily pretreated individuals with HER2-positive breast and gastric cancers A favorable ...</description>
</item>
<item>
<title>EMA Positive Opinion for Orphan Drug Designation to BioInvent's BI‑1808 for the Treatment of Cutaneous T-cell Lymphoma</title>
<link>https://6ix.com/company/bioinvent-international-ab/news/ema-positive-opinion-for-orphan-drug-designation-to-bioinvents-bi1808-for-the-treatment-of-cutaneous-t-cell-lymphoma</link>
<guid isPermaLink="true">https://6ix.com/company/bioinvent-international-ab/news/ema-positive-opinion-for-orphan-drug-designation-to-bioinvents-bi1808-for-the-treatment-of-cutaneous-t-cell-lymphoma</guid>
<pubDate>Mon, 17 Nov 2025 08:15:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / November 17, 2025 /BioInvent International AB ("BioInvent")(Nasdaq Stockholm: BINV)(STO:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer ...</description>
</item>
<item>
<title>BioInvent's BI-1910 Data Validates TNFR2 as a Novel Immunotherapy Approach in Advanced Solid Tumors: Phase 1 Data at SITC 2025</title>
<link>https://6ix.com/company/bioinvent-international-ab/news/bioinvents-bi-1910-data-validates-tnfr2-as-a-novel-immunotherapy-approach-in-advanced-solid-tumors-phase-1-data-at-sitc-2025</link>
<guid isPermaLink="true">https://6ix.com/company/bioinvent-international-ab/news/bioinvents-bi-1910-data-validates-tnfr2-as-a-novel-immunotherapy-approach-in-advanced-solid-tumors-phase-1-data-at-sitc-2025</guid>
<pubDate>Fri, 07 Nov 2025 14:20:00 GMT</pubDate>
<description>BioInvent International (STO:BINV) Twelve patients achieved stable disease, whereof five with disease control lasting over six months; this correlates with strong CD4⁺ and CD8⁺ memory T-cell expansion As previously reported, the single agent dose ...</description>
</item>
<item>
<title>BioInvent to Present Early Phase 2a Data from Ongoing Trial with Triple Combination of BI-1206, Rituximab, and Calquence in r/r NHL, at ASH 2025</title>
<link>https://6ix.com/company/bioinvent-international-ab/news/bioinvent-to-present-early-phase-2a-data-from-ongoing-trial-with-triple-combination-of-bi-1206-rituximab-and-calquence-in-rr-nhl-at-ash-2025</link>
<guid isPermaLink="true">https://6ix.com/company/bioinvent-international-ab/news/bioinvent-to-present-early-phase-2a-data-from-ongoing-trial-with-triple-combination-of-bi-1206-rituximab-and-calquence-in-rr-nhl-at-ash-2025</guid>
<pubDate>Mon, 03 Nov 2025 14:17:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / November 3, 2025 /BioInvent International AB ("BioInvent")(STO:BINV)(Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer ...</description>
</item>
<item>
<title>BioInvent to Present Updated Phase 2a BI-1808 Monotherapy Data in CTCL at ASH 2025</title>
<link>https://6ix.com/company/bioinvent-international-ab/news/bioinvent-to-present-updated-phase-2a-bi-1808-monotherapy-data-in-ctcl-at-ash-2025</link>
<guid isPermaLink="true">https://6ix.com/company/bioinvent-international-ab/news/bioinvent-to-present-updated-phase-2a-bi-1808-monotherapy-data-in-ctcl-at-ash-2025</guid>
<pubDate>Mon, 03 Nov 2025 14:15:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / November 3, 2025 /BioInvent International AB ("BioInvent") (STO:BINV)(Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer ...</description>
</item>
<item>
<title>BioInvent International AB: Interim Report January - September 2025</title>
<link>https://6ix.com/company/bioinvent-international-ab/news/bioinvent-international-ab-interim-report-january-september-2025</link>
<guid isPermaLink="true">https://6ix.com/company/bioinvent-international-ab/news/bioinvent-international-ab-interim-report-january-september-2025</guid>
<pubDate>Wed, 29 Oct 2025 07:20:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / October 29, 2025 / BioInvent International (STO:BINV) "The third quarter of 2025 marked continued momentum for BioInvent as we decided to focus on our most advanced programs BI-1206 and BI-1808. This strategic direction ...</description>
</item>
<item>
<title>Invitation to Presentation of BioInvent's Interim Report January - September 2025</title>
<link>https://6ix.com/company/bioinvent-international-ab/news/invitation-to-presentation-of-bioinvents-interim-report-january-september-2025</link>
<guid isPermaLink="true">https://6ix.com/company/bioinvent-international-ab/news/invitation-to-presentation-of-bioinvents-interim-report-january-september-2025</guid>
<pubDate>Mon, 27 Oct 2025 14:15:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / October 27, 2025 /BioInvent International AB ("BioInvent")(Nasdaq Stockholm:BINV)(STO:BINV) invites investors, analysts and the press to a presentation of the interim report January - September 2025 at 2:00 pm CET on Wednesday ...</description>
</item>
<item>
<title>Transgene and BioInvent's Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors</title>
<link>https://6ix.com/company/bioinvent-international-ab/news/transgene-and-bioinvents-armed-oncolytic-virus-bt-001-shows-positive-local-abscopal-and-sustained-antitumoral-activity-in-advanced-refractory-tumors</link>
<guid isPermaLink="true">https://6ix.com/company/bioinvent-international-ab/news/transgene-and-bioinvents-armed-oncolytic-virus-bt-001-shows-positive-local-abscopal-and-sustained-antitumoral-activity-in-advanced-refractory-tumors</guid>
<pubDate>Mon, 20 Oct 2025 06:50:00 GMT</pubDate>
<description>BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and non-injected lesions Data support further development of BT-001 in solid tumors to improve response to cancer immunotherapy LUND, ...</description>
</item>
<item>
<title>Transgene and BioInvent to Present Translational Data and Updated Clinical Results on Armed Oncolytic Virus BT-001, at ESMO 2025</title>
<link>https://6ix.com/company/bioinvent-international-ab/news/transgene-and-bioinvent-to-present-translational-data-and-updated-clinical-results-on-armed-oncolytic-virus-bt-001-at-esmo-2025</link>
<guid isPermaLink="true">https://6ix.com/company/bioinvent-international-ab/news/transgene-and-bioinvent-to-present-translational-data-and-updated-clinical-results-on-armed-oncolytic-virus-bt-001-at-esmo-2025</guid>
<pubDate>Mon, 13 Oct 2025 06:55:00 GMT</pubDate>
<description>- Updated clinical data on BT-001 in combination with pembrolizumab to be presented in a poster - Tumor shrinkage observed in both injected and non-injected lesions LUND, SE / ACCESS Newswire / October 13, 2025 /BioInvent International AB ("BioInvent") ...</description>
</item>
<item>
<title>BioInvent Announces Initiation of BI-1206 Phase 2a Trial in Advanced or Metastatic NSCLC and Uveal Melanoma</title>
<link>https://6ix.com/company/bioinvent-international-ab/news/bioinvent-announces-initiation-of-bi-1206-phase-2a-trial-in-advanced-or-metastatic-nsclc-and-uveal-melanoma</link>
<guid isPermaLink="true">https://6ix.com/company/bioinvent-international-ab/news/bioinvent-announces-initiation-of-bi-1206-phase-2a-trial-in-advanced-or-metastatic-nsclc-and-uveal-melanoma</guid>
<pubDate>Wed, 08 Oct 2025 06:15:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / October 8, 2025 /BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) (STO:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer ...</description>
</item>
<item>
<title>BioInvent to Present Phase 1 Clinical Data for BI-1910, a TNFR2 Agonist for the Treatment of Solid Tumors, at SITC</title>
<link>https://6ix.com/company/bioinvent-international-ab/news/bioinvent-to-present-phase-1-clinical-data-for-bi-1910-a-tnfr2-agonist-for-the-treatment-of-solid-tumors-at-sitc</link>
<guid isPermaLink="true">https://6ix.com/company/bioinvent-international-ab/news/bioinvent-to-present-phase-1-clinical-data-for-bi-1910-a-tnfr2-agonist-for-the-treatment-of-solid-tumors-at-sitc</guid>
<pubDate>Fri, 03 Oct 2025 13:15:00 GMT</pubDate>
<description>As previously reported, the single agent dose escalation of BI-1910 in the Phase 1 study was completed without any notable adverse events Updated clinical data will be presented at the Society for Immunotherapy of Cancer (SITC) 40th Anniversary Annual ...</description>
</item>
<item>
<title>BioInvent Announces Board of Directors Update</title>
<link>https://6ix.com/company/bioinvent-international-ab/news/bioinvent-announces-board-of-directors-update</link>
<guid isPermaLink="true">https://6ix.com/company/bioinvent-international-ab/news/bioinvent-announces-board-of-directors-update</guid>
<pubDate>Tue, 02 Sep 2025 08:30:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / September 2, 2025 /BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, ...</description>
</item>
<item>
<title>BioInvent Announces Strategic Changes in Portfolio to Accelerate Lead Clinical Programs and Enhance Value Creation</title>
<link>https://6ix.com/company/bioinvent-international-ab/news/bioinvent-announces-strategic-changes-in-portfolio-to-accelerate-lead-clinical-programs-and-enhance-value-creation</link>
<guid isPermaLink="true">https://6ix.com/company/bioinvent-international-ab/news/bioinvent-announces-strategic-changes-in-portfolio-to-accelerate-lead-clinical-programs-and-enhance-value-creation</guid>
<pubDate>Tue, 26 Aug 2025 06:50:00 GMT</pubDate>
<description>Focusing on lead programs BI-1206 and BI-1808, with strong clinical data and upcoming value-creation milestones Phase 2a study of BI-1206 in combination with pembrolizumab in first-line NSCLC to initiate in H2 2025 LUND, SE / ACCESS Newswire / August ...</description>
</item>
<item>
<title>BioInvent International AB: Interim Report January - June 2025</title>
<link>https://6ix.com/company/bioinvent-international-ab/news/bioinvent-international-ab-interim-report-january-june-2025</link>
<guid isPermaLink="true">https://6ix.com/company/bioinvent-international-ab/news/bioinvent-international-ab-interim-report-january-june-2025</guid>
<pubDate>Tue, 26 Aug 2025 06:50:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / August 26, 2025 /BioInvent International (STO:BINV) - "This is an important next step for BioInvent," said Martin Welschof, Chief Executive Officer of BioInvent. "We are sharpening our clinical focus on our most advanced ...</description>
</item>
<item>
<title>Transgene and BioInvent to Present Updated Data on Armed Oncolytic virus BT-001 at ESMO 2025</title>
<link>https://6ix.com/company/bioinvent-international-ab/news/transgene-and-bioinvent-to-present-updated-data-on-armed-oncolytic-virus-bt-001-at-esmo-2025</link>
<guid isPermaLink="true">https://6ix.com/company/bioinvent-international-ab/news/transgene-and-bioinvent-to-present-updated-data-on-armed-oncolytic-virus-bt-001-at-esmo-2025</guid>
<pubDate>Mon, 28 Jul 2025 06:50:00 GMT</pubDate>
<description>- Poster presentation of updated data on BT-001 from the Phase 1 part of the ongoing Phase 1/2a study in solid tumors - LUND, SE / ACCESS Newswire / July 28, 2025 /BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company ...</description>
</item>
</channel>
</rss>